in the interview, a good point was made, being the multiple...

in the interview, a good point was made, being the multiple avenues to revenue Anteotech has with it's expanding range of products and partnerships.

ev1 partnership has proved in the last year, performance improvement, cost saving, being able to transfer anteo's tech to manufacture a full anode, reach 1000 cycles. this is only for about a 20% silicon anode with anteoX added

a completely different project, than with ev2 that are working with our high silicon anode tech.

which will be different to the milestones and battery configurations we are dealing with in the other 5 ev companies.

and then you have several consumer electronic companies working with us. they have a different cycle need and performance level again. we are (IMO) working with a customer who supplies batteries to apple. they will have different requirements than a power tool battery or drone battery etc

and then we have giga factories as well

and then we are dealing with a nanotube company

and then we are dealing with a separator manufacturer.

we only need one big marquee company to sign or several smaller to multi bag from here.

then we have our life science division dealing with vaccine manufacturers, poc companies dealing with medical, veterinary, environmental etc.

we aren't going to sign all 18+ CET partners and 9+ life science partners to commercial deals (if we do our sp will be up in the asx20 ).

if we just commercialise our tech to demand of 100k litres that we will be able to produce in our production facility, and add a couple of life science deals we will be multi bagging. each deal added will be cream on top of that.

next few months are going to be telling for this little spec company. GLTAH, IMO, DYOR